Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab | Zendy

Muaaz Masood | Zendy; Michael Coles | Zendy; Humberto Sifuentes | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab

Author(s) -

Muaaz Masood,

Michael Coles,

Humberto Sifuentes

Publication year - 2021

Publication title -

case reports in gastrointestinal medicine

Language(s) - English

Resource type - Journals

eISSN - 2090-6528

pISSN - 2090-6536

DOI - 10.1155/2021/2242178

Subject(s) - medicine , telangiectasia , bevacizumab , sequela , gastrointestinal bleeding , refractory (planetary science) , angiogenesis , vascular endothelial growth factor , arteriovenous malformation , pathology , gastroenterology , vegf receptors , surgery , chemotherapy , physics , astrobiology

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder resulting in vascular malformations of several organs including the pulmonary, cerebral, and gastrointestinal systems. One sequela is recurrent gastrointestinal (GI) bleeding. Bevacizumab (Bev) is emerging as an effective treatment of recurrent gastrointestinal bleeding in HHT. Bev is a recombinant monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), an integral part of angiogenesis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research